Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Jam tomorrow

This article was originally published in Scrip

Executive Summary

The Private Securities Litigation Reform Act of 1995, or Forward-Looking Statement Safe Harbor disclaimer as it is better known, advises investors that under such a disclaimer, companies can make financial projections and statements on clinical trial success or approval for their drugs, without fear of repercussion if those statements fail to be true. Additionally, having promised the moon, companies are under no obligation to update investors if they fail to deliver whatever promises were previously made under the Safe Harbor disclaimer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC025341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel